Epizyme, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2007-01-01
- Employees
- 250
- Market Cap
- -
- Website
- http://www.epizyme.com
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation
- Conditions
- Interventions
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT06068881
A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
- Conditions
- Interventions
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- Epizyme, Inc.
- Registration Number
- NCT05205252
- Locations
- 🇺🇸
Central Care Cancer Center, Bolivar, Missouri, United States
🇺🇸California Cancer Associates For Research And Excellence, cCARE, Santa Fe, California, United States
🇺🇸Astera Cancer Center, East Brunswick, New Jersey, United States
A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT05121103
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Astera Cancer Care, East Brunswick, New Jersey, United States
🇺🇸Weill Cornell Medicine, New York, New York, United States
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT04762160
- Locations
- 🇺🇸
XCancer/ Northwest Oncology & Hematology, Rolling Meadows, Illinois, United States
🇺🇸Compassionate Cancer Care, Fountain Valley, California, United States
🇺🇸USOR/ Illinois Cancer Specialists, Niles, Illinois, United States
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
- Conditions
- Interventions
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT04537715
- Locations
- 🇪🇸
Onkologikoa, Donostia, Gipuzkoa, Spain
🇺🇸California Cancer Associates for Research and Excellence, Inc. (cCARE), Encinitas, California, United States
🇺🇸Northwestern University-Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
- Conditions
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04241835
- Locations
- 🇺🇸
Rutgers Cancer Institute, New Brunswick, New Jersey, United States
🇺🇸Florida Cancer Specialists & Research Institute, Lake Mary, Florida, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 612
- Registration Number
- NCT04224493
- Locations
- 🇦🇺
GenesisCare - St Andrew's, Adelaide, Australia
🇮🇹Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda, Milano, Italy
🇮🇹Ospedale San Gerardo, ASST di Monza, Monza, Italy
Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma
- Conditions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Epizyme, Inc.
- Registration Number
- NCT04225429
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 164
- Registration Number
- NCT04204941
- Locations
- 🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States
🇺🇸University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT04179864
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Genesis Healthcare Partners, San Diego, California, United States